Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease

Innovent Biologics (HKEX: 01801) presented preclinical data for IAR177, a bispecific antibody targeting IL-6 and TL1A, at ACR Convergence 2026. The data suggests superior efficacy in rheumatoid arthritis models compared to single-target treatments. Innovent aims to advance IAR177 for potential disease modification and remission in rheumatic diseases.

Innovent Biologics (IVBXF) reported that its Phase 3 trial for Sintbilo (tafolecimab) met primary and secondary endpoints, reducing LDL cholesterol by over 60% at Week 12. The trial involved 198 participants in China. The company plans to file for a new indication in China. IVBXF closed at $11.10 on Friday.

Innovent Biologics (HKEX: 01801) announced that its drug SINTBILO® (tafolecimab) met the primary endpoint in a Phase 3 study, showing significant LDL-C reduction in hyperlipidemia patients. The study demonstrated over 60% mean LDL-C reduction after 12 weeks, with favorable safety profiles. Innovent plans to submit a new indication application to China's NMPA.

Innovent Biologics' application for sintilimab and GC101 combo therapy for advanced melanoma was accepted by China's NMPA. The submission is based on a Phase II trial showing improved progression-free survival. If approved, it will be sintilimab's 11th indication. The therapy is co-developed with Eli Lilly and involves Juncell Therapeutics' GC101.

Innovent Biologics (HKEX: 01801) announced that the NMPA accepted its application for sintilimab in combination with Nolgileucel for treating advanced melanoma. The application is based on Phase II trial results showing improved progression-free survival. If approved, it would be the 11th indication for sintilimab, reinforcing its role in immuno-oncology.

Innovent Biologics presented Phase 2 data for IBI354, a HER2-targeted ADC, at the 2026 ESMO Congress. The drug, combined with pertuzumab, showed a 95% objective response rate and favorable safety in first-line HER2-positive breast cancer. Innovent has initiated Phase 3 trials for IBI354 and plans further studies. The company aims to expand its ADC pipeline and improve cancer treatments.